Reactions Weekly

, Volume 1733, Issue 1, pp 238–238 | Cite as

Multiple drugs

Aggravation of known mild chronic renal insufficiency and chronic renal failure: 2 case reports
Case report
Author Information

An event is serious (based on the ICH definition) when the patient outcome is:

  • * death

  • * life-threatening

  • * hospitalisation

  • * disability

  • * congenital anomaly

  • * other medically important event

In a case report, a 23-year-old man developed chronic renal failure during treatment with zoledronic-acid [zoledronate] for bone metastasis cancer and with cabozantinib for metastatic medullary thyroid cancer (MTC), and a 67-year-old man developed aggravation of known mild chronic renal insufficiency leading to chronic renal failure during treatment with lenvatinib for metastatic papillary thyroid carcinoma and with iomeprol [Imeron] and iopromide [Ultravist-370] used an an contrast media.

Patient 1: A 23-year-old man was diagnosed with metastatic MTC. He was enrolled in the phase III study comparing cabozantinib to placebo. He received blinded treatment for 3 weeks. On day 1 of study treatment, he had a normal renal function. He received cabozantinib for metastatic MTC. He had...


  1. Paschke L, et al. Anti VEGF-TKI Treatment and New Renal Adverse Events Not Reported in Phase III Trials. European Thyroid Journal 7: 308-312, No. 6, Nov 2018. Available from: URL: - Germany

Copyright information

© Springer Nature Switzerland AG 2018

Personalised recommendations